Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Antimicrob Agents Chemother ; 51(1): 198-207, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17088485

RESUMEN

Molecular characterization of fluoroquinolone-resistant Streptococcus pneumoniae in Canada was conducted from 1997 to 2005. Over the course of the study, 205 ciprofloxacin-resistant isolates were evaluated for ParC and GyrA quinolone resistance-determining region (QRDR) substitutions, substitutions in the full genes of ParC, ParE, and GyrA, reserpine sensitivity, and serotype and by pulsed-field gel electrophoresis. Rates of ciprofloxacin resistance of S. pneumoniae increased significantly, from less than 1% in 1997 to 4.2% in 2005. Ciprofloxacin resistance was greatest in people >64 years of age and least in those <16 years of age. Significant increases were also noted in rates of resistance to gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin, to the current rates of 1.6%, 1.0%, 1.1%, and 1.0%, respectively. The most common genotype observed consisted of QRDR substitutions in GyrA (Ser81Phe) and ParC (Ser79Phe). Substitutions outside the QRDR of GyrA, ParC, and ParE were not associated with fluoroquinolone resistance in this study. Overall, 21% of isolates were reserpine-sensitive and were thus assumed to be efflux positive. The ciprofloxacin-resistant isolates belonged to 35 different serotypes, but 10 (19F, 11A, 23F, 6B, 22F, 12F, 6A, 14, 9V, and 19A) accounted for 72% of all isolates. The majority of the isolates were found to be genetically unrelated by pulsed-field gel electrophoresis. Within the observed clusters, there was considerable genetic heterogeneity with regard to fluoroquinolone resistance mechanisms and serotypes. Continued surveillance and molecular analysis of fluoroquinolone-resistant S. pneumoniae in Canada are essential for appropriate empirical treatment of infections and early detection of novel resistance mechanisms.


Asunto(s)
Farmacorresistencia Bacteriana/genética , Fluoroquinolonas/farmacología , Streptococcus pneumoniae/efectos de los fármacos , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Compuestos Aza/farmacología , Proteínas Bacterianas/genética , Canadá/epidemiología , Niño , Preescolar , Ciprofloxacina/farmacología , Electroforesis en Gel de Campo Pulsado , Gatifloxacina , Gemifloxacina , Genotipo , Humanos , Lactante , Recién Nacido , Levofloxacino , Persona de Mediana Edad , Moxifloxacino , Naftiridinas/farmacología , Ofloxacino/farmacología , Infecciones Neumocócicas/epidemiología , Infecciones Neumocócicas/microbiología , Quinolinas/farmacología , Serotipificación , Streptococcus pneumoniae/clasificación , Streptococcus pneumoniae/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA